Format

Send to

Choose Destination
Clin Lymphoma Myeloma Leuk. 2019 Apr 5. pii: S2152-2650(19)30169-7. doi: 10.1016/j.clml.2019.03.030. [Epub ahead of print]

p53 and β-Catenin Expression Predict Poorer Prognosis in Patients With Anaplastic Large-Cell Lymphoma.

Author information

1
Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS.
2
Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX.
3
Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS; Stowers Institute for Medical Research, Kansas City, MO.
4
Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS. Electronic address: dzhang@kumc.edu.

Abstract

BACKGROUND:

The Wnt/β-catenin signaling pathway is a major target of p53. β-Catenin/p53 coexpression predicts poorer survival in carcinoma patients. Conversely, CD99 inhibits tumor metastasis through the Wnt/β-catenin pathway. We therefore assessed p53, β-catenin, and CD99 by immunohistochemistry.

PATIENTS AND METHODS:

We studied 45 patients with systemic anaplastic large-cell lymphoma (ALCL), including 20 anaplastic lymphoma kinase (ALK)-positive and 25 ALK-negative ALCL. β-Catenin expression was analyzed using phospho-β-catenin-S552 antibody because its nuclear localization indicates Wnt signaling.

RESULTS:

In this cohort, p53 expression was associated with ALK-negative ALCL. Furthermore, p53 or β-catenin expression alone or β-catenin/p53 double expression showed poorer overall survival and disease-free survival in patients with ALCL overall and in patients with ALK-negative ALCL. CD99 expression was more frequent in ALK-positive ALCL but had no prognostic significance.

CONCLUSION:

This is the first study to evaluate phospho-β-catenin-S552 expression in ALCL. The results of this study, although limited by small patient size, suggest that β-catenin and p53 may play a role in pathogenesis and may be helpful in risk stratification of ALCL patients.

KEYWORDS:

ALCL; ALK; Survival; Wnt signaling; β-Catenin

PMID:
31078446
DOI:
10.1016/j.clml.2019.03.030

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center